Biodistribution studies of 99mTc-labeled myoblasts in a murine model of muscular dystrophy

Nucl Med Biol. 2001 Nov;28(8):935-40. doi: 10.1016/s0969-8051(01)00256-6.

Abstract

The purpose of this study was twofold: first, to evaluate the myoblast labeling of various 99mTc complexes and to select the complex that best accomplishes this labeling, and second to evaluate the biodistribution of myoblasts labeled with this complex using mice with MDX muscular dystrophy (the murine homologue of Duchenne's muscular dystrophy). The following ligands were used to prepare the corresponding 99mTc complexes: hexakis-methoxy-isobutyl-isonitrile (MIBI), bis(2-ethoxyethyl)diphosphinoethane (Tf), (RR,SS)-4,8-diaza-3,6,6,9-tetramethyl-undecane-2,10-dione-bisoxime (HM-PAO), bis(N-ethyl)dithiocarbamate (NEt), and bis(N-ethoxy, N-ethyl)dithiocarbamate (NOEt). One million murine myoblasts were incubated for 30-60 minutes with 5 mCi of each of the 99mTc complexes prepared from the above ligands. Viability was assessed by microscopic counting after trypan blue staining, and the radioactivity absorbed in the cells was measured after centrifugation. The compound with the highest uptake in cellular pellets was [99mTc]N-NOEt. The biodistribution of myoblasts labeled with this complex was evaluated after intraaortic injection in dystrophic mice. Such an approach has the potential of effecting widespread gene transfer through the bloodstream to muscles lacking dystrophin.

MeSH terms

  • Animals
  • Cell Transplantation
  • Cells, Cultured
  • Genetic Therapy
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Skeletal / cytology
  • Muscle, Skeletal / metabolism
  • Muscle, Skeletal / transplantation*
  • Muscular Dystrophy, Animal / metabolism*
  • Muscular Dystrophy, Animal / therapy
  • Technetium / pharmacokinetics*
  • Tissue Distribution

Substances

  • Technetium